인슐린 펌프 시장 : 유형별, 제품별, 액세서리별, 질환별, 연령대별, 최종사용자별, 유통 채널별, 지역별, 기회 및 예측(2017-2031년)

Global insulin pumps market size was valued at USD 6.78 billion in 2023, which is expected to reach USD 17.12 billion in 2031, with a CAGR of 12.28% for the forecast period between 2024 and 2031F. The key factors propelling the global insulin pumps market include a surge in the prevalence of diabetes, a growing need for insulin delivery devices that offer convenience and user-friendliness, advancements in technology, governmental efforts, and an increasing elderly population.

The global insulin pumps market is expected to gain a substantial transformation and expansion, driven by a convergence of factors that are reshaping the realm of diabetes management. One of the principal catalysts propelling the market's growth is the escalating prevalence of diabetes. The alarming surge in diabetes cases, encompassing both type 1 and type 2, has generated an urgent requirement for dependable and convenient means of administering insulin. As patients and healthcare practitioners seek more efficacious methods for regulating blood glucose levels, insulin pumps have emerged as the favored choice due to their capacity to deliver precise doses with minimal exertion.

Moreover, the global insulin pumps market is capitalizing on technological advancements. The incorporation of continuous glucose monitoring (CGM), the emergence of intelligent insulin pumps, and improvements in user interfaces have transformed these devices into more user-friendly and efficient tools. Patients are increasingly in search of devices that provide precise insulin delivery and seamlessly integrate with smartphones and other digital platforms, enabling real-time data monitoring and management.

Additionally, governmental efforts aimed at alleviating the diabetes burden and associated healthcare costs are fostering the global insulin pumps market's growth. Public health initiatives and policies designed to encourage the adoption of advanced diabetes management technologies have contributed to heightened accessibility and affordability of insulin pumps.

Rising Diabetes Prevalence

Globally, the population of individuals living with diabetes (PLWD) has witnessed a substantial surge over the past three decades, soaring from 108 million to 420 million. Among these, 62 million individuals with diabetes reside in the Americas, largely impacting the global insulin pumps market. Notably, the number has ballooned by more than threefold in the region since 1980, with the actual figure being potentially higher, as 40% of PLWD remain unaware of their condition, going undiagnosed. The burden posed by diabetes-related health issues is both significant and escalating. Within two decades, diabetes-related mortality has escalated by a staggering 70% worldwide.

In the Americas, it stands as the sixth leading cause of death and the seventh leading contributor to years of life lost prematurely. In the region, diabetes, inclusive of diabetes-related kidney disease, accounts for the premature loss of more than eight million years of life annually. Astonishingly, almost half of premature deaths in the Americas are attributed to diabetes. Furthermore, over a span of just 20 years, the number of disability-adjusted life years (DALYs) attributable to diabetes has surged by 88%, reaching a remarkable 97% increase among men. Presently, diabetes ranks as the second leading cause of DALYs globally, trailing behind ischemic heart disease.

Rising Demand for Algorithms for Automated Insulin Delivery

The increasing desire for algorithms in automated insulin delivery signifies a significant shift in diabetes care. These algorithms, powered by advanced technologies, offer precise and adaptable insulin control. With the global diabetes prevalence on the rise, there's a pronounced demand for inventive solutions to simplify and improve insulin management. The growing demand for insulin delivery algorithms is opening doors for companies specializing in these technologies. Firms capable of creating precise, dependable, and user-friendly algorithms are poised to thrive in the expanding global insulin pumps market. As an example, in May 2023, Beta Bionics obtained approval from the US Food and Drug Administration (FDA) for its iLet ACE Pump and iLet Dosing Decision Software, designed for individuals aged six years and older with type 1 diabetes. These components, when used in conjunction with a compatible integrated continuous glucose monitor (iCGM), constitute the iLet Bionic Pancreas system. The innovative system employs an algorithm to assess and regulate insulin delivery.

Government Initiatives

Government actions are central in molding the global insulin pumps market's characteristics, impacting its accessibility, affordability, and the uptake of advanced technologies for managing diabetes. These governmental endeavors are vital in confronting the escalating issue of diabetes, a persistent metabolic ailment marked by elevated blood glucose levels that afflict a vast global population. The greater the extent to which governments can assist patients in acquiring the skills for self-management, the lower the long-term healthcare costs it will incur due to improved health outcomes and reduced costs for the entire population.

For instance, in March 2023, the government of New Brunswick unveiled its plan to alleviate the financial burden associated with diabetes. Minister of Finance Ernie Steeves announced a budget allocation of USD 2.1 million to improve diabetes management. In New Brunswick, annual expenses directly borne by individuals can surpass USD 18,000 for those with Type 1 diabetes and USD 10,000 for those with Type 2 diabetes, as reported by Diabetes Canada. The province's announcement is expected to target and alleviate a significant portion of the high costs linked with diabetes.

Growing Demand for Insulin Patch

The increasing desire for insulin patches marks a noteworthy transformation in the global insulin pump market. Insulin patches present a non-intrusive and unobtrusive means of administering insulin, potentially enhancing the well-being of individuals living with diabetes. The surging appeal of these patches can be traced to their convenience, precision, and ability to address certain obstacles linked to conventional insulin delivery approaches.

As an illustration, in May 2023, Medtronic plc, a prominent player in healthcare technology, disclosed its intent to finalize a series of agreements aimed at acquiring EOFlow Co. Ltd., the creator of the EOPatch device, an insulin delivery device that is both tubeless and disposable, designed to be worn on the body. The incorporation of EOFlow into Medtronic's portfolio, in conjunction with the company's Meal Detection Technology algorithm and state-of-the-art continuous glucose monitor (CGM), is poised to enhance Medtronic's capacity to cater to the diverse requirements of individuals with diabetes, regardless of their stage in the treatment process or their preferences for insulin delivery methods. Such convenience-based products are the leading cause for drastic growth in global insulin pump market.

Increasing Demand for Type 1 Diabetes Solutions

The intricate challenges of mealtimes in type 1 diabetes management drive the demand for solutions and stimulate growth in the global insulin pumps market. Balancing insulin dosages with carbohydrate intake, managing blood sugar spikes post-meal, and predicting meal content can be formidable tasks. The challenge lies in maintaining glycemic control and preventing hypoglycemia or hyperglycemia during and after meals. CGM, advanced insulin delivery systems, and mealtime planning have become essential strategies to address these challenges and enhance diabetes management. As an example, in April 2023, Medtronic plc, a leading global medical technology company, revealed that the U.S. Food and Drug Administration (FDA) had approved its MiniMed 780G system, featuring the Guardian 4 sensor, which eliminates the need for fingerstick tests when using SmartGuard technology. This achievement signifies the approval of the sole system incorporating meal detection technology, enabling automatic adjustments and corrections to sugar levels every 5 minutes, proving highly advantageous for individuals with type 1 diabetes.

Impact of COVID-19

Patients with T1DM using insulin pumps experienced a milder impact from COVID-19 lockdown measures on their glycemic control than those using insulin pens. The adoption of telemedicine and online consultations yielded substantial benefits, optimizing time allocation per patient, and improving physician-patient communication. Physicians could remotely monitor disease progression, resulting in significant improvements. Notably, insulin pump users exhibited superior glycemic stability and better resilience to pandemic-related stress and anxiety compared to pen users. The advantage may be attributed to the continuous glycemic monitoring system, which is likely contributed to fewer hyperglycemic episodes in the group. However, the pandemic had some adverse effects on the global insulin pumps market, as several insulin pump manufacturers deferred or put on hold the introduction of new products or enhancements because of the uncertainties stemming from the pandemic.

Key Players Landscape and Outlook

Collaborative efforts in the global insulin pumps market are witnessing a surge as companies aim to pioneer novel and inventive technologies for the betterment of individuals with diabetes. Recent instances of such collaborations include Medtronic teaming up with Bigfoot Biomedical to co-create a hybrid closed-loop insulin delivery system, and Tandem Diabetes Care partnering with Dexcom to seamlessly integrating their insulin pumps with Dexcom's continuous glucose monitoring (CGM) system. These partnerships are pivotal in expediting the development of next-generation insulin pumps characterized by enhanced accuracy, convenience, and user-friendliness.

For example, in August 2023, Modular Medical, Inc. joined forces with Phillips-Medisize to broaden the array of insulin delivery options. Leveraging its extensive and diverse supplier network, as well as its profound expertise in medical devices and diabetes management, Phillips-Medisize took charge of designing and developing the manufacturing and assembly processes for the MODD1 Insulin Delivery System. The collaboration has expedited the development journey for Modular Medical and has paved the way for substantial scalability and a state of readiness for market launch.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of Covid-19 on Global Insulin Pumps Market

4. Executive Summary

5. Global Insulin Pumps Market Outlook, 2017-2031F

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. By Volume
• 5.2. By Type
  • 5.2.1. Standalone Insulin Pumps
  • 5.2.2. Sensor Integrated Insulin Pumps
• 5.3. By Product
  • 5.3.1. Pumps
    • 5.3.1.1. Tethered Pumps
    • 5.3.1.2. Patch Pumps
    • 5.3.1.3. Others
  • 5.3.2. Consumables
• 5.4. By Accessories
  • 5.4.1. Insulin Reservoir or Cartridges
  • 5.4.2. Insulin Set Insertion Devices
  • 5.4.3. Battery
• 5.5. By Disease Indication
  • 5.5.1. Type 1 Diabetes
  • 5.5.2. Type 2 Diabetes
• 5.6. By Age Group
  • 5.6.1 Adult
  • 5.6.2. Paediatrics
  • 5.6.3. Both
• 5.7. By End-user
  • 5.7.1. Hospitals
  • 5.7.2. Clinics
  • 5.7.3. Homeware
  • 5.7.4. Laboratories
• 5.8. By Distribution Channel
  • 5.6.1 Retail Stores
  • 5.6.2 Hospital Pharmacy
  • 5.6.3 E-commerce
• 5.9. By Region
  • 5.9.1. North America
  • 5.9.2. South America
  • 5.9.3. Europe
  • 5.9.4. Asia-Pacific
  • 5.9.5. Middle East and Africa
• 5.10. By Company Market Share (%), 2023

6. Global Insulin Pumps Market Outlook, By Region, 2017-2031F

• 6.1. North America*
  • 6.1.1. Market Size & Forecast
    • 6.1.1.1. Value
    • 6.1.1.2. Volume
  • 6.1.2. By Type
    • 6.1.2.1. Standalone Insulin Pumps
    • 6.1.2.2. Sensor Integrated Insulin Pumps
  • 6.1.3. Product
    • 6.1.3.1. Pumps
    • 6.1.3.1.1. Tethered Pumps
    • 6.1.3.1.2. Patch Pumps
    • 6.1.3.1.3. Others
    • 6.1.3.2. Consumables
  • 6.1.4. By Accessories
    • 6.1.4.1. Insulin Reservoir or Cartridges
    • 6.1.4.2. Insulin Set Insertion Devices
    • 6.1.4.3. Battery
  • 6.1.5. By Disease Indication
    • 6.1.5.1. Type 1 Diabetes
    • 6.1.5.2. Type 2 Diabetes
  • 6.1.6. By Age Group
    • 6.1.6.1. Adult
    • 6.1.6.2. Pediatric
    • 6.1.6.3. Both
  • 6.1.7. By End-user
    • 6.1.7.1. Hospitals
    • 6.1.7.2. Clinics
    • 6.1.7.3. Homeware
    • 6.1.7.4. Laboratories
  • 6.1.8. By Distribution Channel
    • 6.1.8.1. Retail Stores
    • 6.1.8.2. Hospital Pharmacy
    • 6.1.8.3. E-commerce
  • 6.1.9. United States*
    • 6.1.9.1. Market Size & Forecast
    • 6.1.9.1.1. Value
    • 6.1.9.1.2. Volume
    • 6.1.9.2. By Type
    • 6.1.9.2.1. Standalone Insulin Pumps
    • 6.1.9.2.2. Sensor Integrated Insulin Pumps
    • 6.1.9.3. By Product
    • 6.1.9.3.1. Pumps
    • 6.1.9.3.1.1. Tethered Pumps
    • 6.1.9.3.1.2. Patch Pumps
    • 6.1.9.3.1.3. Others
    • 6.1.9.3.2. Consumables
    • 6.1.9.4. By Accessories
    • 6.1.9.4.1. Insulin Reservoir or Cartridges
    • 6.1.9.4.2. Insulin Set Insertion Devices
    • 6.1.9.4.3. Battery
    • 6.1.9.5. By Disease Indication
    • 6.1.9.5.1. Type 1 Diabetes
    • 6.1.9.5.2. Type 2 Diabetes
    • 6.1.9.6. By Age Group
    • 6.1.9.6.1. Adult
    • 6.1.9.6.2. Pediatric
    • 6.1.9.6.3. Both
    • 6.1.9.7. By End-user
    • 6.1.9.7.1. Hospitals
    • 6.1.9.7.2. Clinics
    • 6.1.9.7.3. Homeware
    • 6.1.9.7.4. Laboratories
    • 6.1.9.8. By Distribution Channel
    • 6.1.9.8.1. Retail Stores
    • 6.1.9.8.2. Hospital Pharmacy
    • 6.1.9.8.3. E-commerce
  • 6.1.10. Canada
  • 6.1.11. Mexico

All segments will be provided for all regions and countries covered:

• 6.2. Europe
  • 6.2.1 Germany
  • 6.2.2 France
  • 6.2.3 Italy
  • 6.2.4 United Kingdom
  • 6.2.5 Russia
  • 6.2.6 Netherlands
  • 6.2.7 Spain
  • 6.2.8 Turkey
  • 6.2.9 Poland
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Argentina
• 6.4. Asia-Pacific
  • 6.4.1. India
  • 6.4.2. China
  • 6.4.3. Japan
  • 6.4.4. Australia
  • 6.4.5. Vietnam
  • 6.4.6. South Korea
  • 6.4.7. Indonesia
  • 6.4.8. Philippines
• 6.5. Middle East & Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. South Africa

7. Market Mapping, 2023

• 7.1. By Type
• 7.2. By Product
• 7.3. By Accessories
• 7.4. By Disease Indication
• 7.5. By Age Group
• 7.6. By End-user
• 7.7. By Distribution Channel
• 7.8. By Region

8. Macro Environment and Industry Structure

• 8.1. Supply Demand Analysis
• 8.2. Import Export Analysis
• 8.3. Value Chain Analysis
• 8.4. PESTEL Analysis
  • 8.4.1. Political Factors
  • 8.4.2. Economic System
  • 8.4.3. Social Implications
  • 8.4.4. Technological Advancements
  • 8.4.5. Environmental Impacts
  • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 8.5. Porter's Five Forces Analysis
  • 8.5.1. Supplier Power
  • 8.5.2. Buyer Power
  • 8.5.3. Substitution Threat
  • 8.5.4. Threat from New Entrant
  • 8.5.5. Competitive Rivalry

9. Market Dynamics

• 9.1. Growth Drivers
• 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

• 10.1 Clinical Trials
• 10.2 Patent Landscape
• 10.3 Regulatory Approvals
• 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)
• 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. Medtronic plc.
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Key Market Focus & Geographical Presence
  • 14.1.6. Recent Developments
• 14.2. Abbott Laboratories
• 14.3. Ypsomed AG
• 14.4. CamDiab Ltd.
• 14.5. Phillips-Medisize Corporation
• 14.6. Modular Medical, Inc.
• 14.7. Tandem Diabetes Care, Inc.
• 14.8. Roche Diabetes Care, Inc.
• 14.9. Beta Bionics
• 14.10. Insulet Corporation
• 14.11. Jiangsu Delfu Medical Device Co., Ltd.
• 14.12. WUXI APEX Medical Corporation
• 14.13. SOOIL Developments Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer